Abbonarsi

Cigarette Smoking and Structural Brain Deficits in Patients With Atrial Fibrillation - 22/01/25

Doi : 10.1016/j.amjcard.2024.11.008 
Raffaele Peter, MD a, b, Stefanie Aeschbacher, PhD a, b, Rebecca E. Paladini, PhD a, b, Michael Coslovsky, PhD a, b, c, Philipp Krisai, MD a, b, Adrian Schweigler, MD a, b, Tobias Reichlin, MD d, Nicolas Rodondi, MD e, f, Andreas Müller, MD g, Moa Haller, MD e, h, Merit Röhl, MD d, Annina Stauber, MD g, i, Tim Sinnecker, MD j, Leo H. Bonati, MD k, l, Thilo Burkard, MD b, m, David Conen, MD n, Stefan Osswald, MD a, b, Michael Kühne, MD a, b, Christine S. Zuern, MD a, b,
a Cardiovascular Research Institute Basel, University Hospital Basel, University of Basel, Basel, Switzerland 
b Cardiology Division, Department of Medicine, University Hospital Basel, University of Basel, Basel, Switzerland 
c Department of Clinical Research, University Hospital Basel, University of Basel, Basel, Switzerland 
d Department of Cardiology, Bern University Hospital, University of Bern, Bern, Switzerland 
e Institute of Primary Health Care, University of Bern, Bern, Switzerland 
f Department of General Internal Medicine, Inselspital, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland 
g Department of Cardiology, Triemli Hospital Zürich, Zürich, Switzerland 
h Faculty of Medicine, University of Bern, Bern, Switzerland 
i Department of Cardiology, Kantonsspital Winterthur, Winterthur, Switzerland 
j Medical Image Analysis Center (MIAC) and Department of Biomedical Engineering, University of Bern, Bern, Switzerland 
k Department of Neurology and Stroke Center, University of Basel, Basel, Switzerland 
l Research Department, Reha Rheinfelden, Rheinfelden, Switzerland 
m Medical Outpatient Department and Hypertension Clinic, ESH Hypertension Centre of Excellence, University Hospital Basel, Basel, Switzerland 
n Population Health Research Institute, McMaster University, Hamilton, Ontario, Canada 

Corresponding author.

Riassunto

Cigarette smoking and atrial fibrillation (AF) are associated with impaired brain health. We investigated the association between smoking habits and brain lesions and volume in patients with AF. In patients with AF from a multicenter cohort study, we assessed smoking status (never, ex-, active), number of cigarettes smoked per day, smoking duration (years), pack-years, and time since smoking cessation. On brain magnetic resonance imaging, the prevalence and volumes of white matter lesions (WML) and small noncortical infarcts, and the volumes of gray matter and white matter were evaluated. Logistic and linear regression analyses were used to analyze the association between smoking habits and brain lesions and volumes. A total of 1,728 patients were enrolled (mean age 72.6 years, 27.5% female); 7.5% were active smokers; 48.5% were ex-smokers, and 44% had never smoked. We found linear associations of number of cigarettes smoked per day, pack-years, and older age at smoking cessation with reduced gray matter volume (p for linear trend <0.01, 0.02, and 0.01, respectively). Patients with a smoking duration in the second and third tertile had a greater risk for WML Fazekas ≥2 (odds ratio 1.86, 95% confidence interval 1.29 to 2.69, p <0.01 and 1.47 [1.02 to 2.12], p = 0.04), and exhibited larger WML volumes. Patients who had stopped smoking ≥16 years before enrollment were less likely to have small noncortical infarcts (odds ratio 0.46, 0.25 to 0.88, p = 0.02) and had smaller WML volumes (β: −0.451 mm3, −0.8 to −0.11, p = 0.01). In conclusion, smoking intensity and time since smoking cessation were associated with the presence and volume of brain lesions and with brain volumes in patients with AF.

Il testo completo di questo articolo è disponibile in PDF.

Keywords : atrial fibrillation, brain deficits, smoking, smoking cessation


Mappa


 The Swiss Atrial Fibrillation study is supported by grants of the Swiss National Science Foundation (Wildhainweg 3, 3001 Bern, CH), Grant numbers 33CS30_148474, 33CS30_177520, 32473B_176178, and 32003B_197524, the Swiss Heart Foundation (Dufourstrasse 30 3005 Bern), the Foundation for Cardiovascular Research Basel (Basel Spitalstr. 2 CH-4056 Basel, CH) , and the University of Basel (Petersplatz 1, 4001 Basel Switzerland).


© 2024  Elsevier Inc. Tutti i diritti riservati.
Aggiungere alla mia biblioteca Togliere dalla mia biblioteca Stampare
Esportazione

    Citazioni Export

  • File

  • Contenuto

Vol 237

P. 72-78 - febbraio 2025 Ritorno al numero
Articolo precedente Articolo precedente
  • Abbreviated Duke Activity Status Index for Risk Stratification in Heart Failure
  • Silvio Nunes Augusto, Yuping Wu, Thanat Chaikijurajai, Stanley L. Hazen, W. H. Wilson Tang
| Articolo seguente Articolo seguente
  • A Multicenter Evaluation of the Impact of Therapies on Deep Learning-Based Electrocardiographic Hypertrophic Cardiomyopathy Markers
  • Lovedeep S. Dhingra, Veer Sangha, Arya Aminorroaya, Robyn Bryde, Andrew Gaballa, Adel H. Ali, Nandini Mehra, Harlan M. Krumholz, Sounok Sen, Christopher M. Kramer, Matthew W. Martinez, Milind Y. Desai, Evangelos K. Oikonomou, Rohan Khera

Benvenuto su EM|consulte, il riferimento dei professionisti della salute.
L'accesso al testo integrale di questo articolo richiede un abbonamento.

Già abbonato a @@106933@@ rivista ?

@@150455@@ Voir plus

Il mio account


Dichiarazione CNIL

EM-CONSULTE.COM è registrato presso la CNIL, dichiarazione n. 1286925.

Ai sensi della legge n. 78-17 del 6 gennaio 1978 sull'informatica, sui file e sulle libertà, Lei puo' esercitare i diritti di opposizione (art.26 della legge), di accesso (art.34 a 38 Legge), e di rettifica (art.36 della legge) per i dati che La riguardano. Lei puo' cosi chiedere che siano rettificati, compeltati, chiariti, aggiornati o cancellati i suoi dati personali inesati, incompleti, equivoci, obsoleti o la cui raccolta o di uso o di conservazione sono vietati.
Le informazioni relative ai visitatori del nostro sito, compresa la loro identità, sono confidenziali.
Il responsabile del sito si impegna sull'onore a rispettare le condizioni legali di confidenzialità applicabili in Francia e a non divulgare tali informazioni a terzi.


Tutto il contenuto di questo sito: Copyright © 2026 Elsevier, i suoi licenziatari e contributori. Tutti i diritti sono riservati. Inclusi diritti per estrazione di testo e di dati, addestramento dell’intelligenza artificiale, e tecnologie simili. Per tutto il contenuto ‘open access’ sono applicati i termini della licenza Creative Commons.